Research programme: central nervous system therapeutics - Alkermes

Drug Profile

Research programme: central nervous system therapeutics - Alkermes

Latest Information Update: 04 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alkermes plc
  • Class Small molecules
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research CNS disorders

Most Recent Events

  • 16 Dec 2016 Early research in CNS disorders in Ireland (unspecified route)
  • 16 Dec 2016 Domain Therapeutics signs a licensing agreement for its GPCR BioSens-All™ technology with Alkermes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top